Cytosorbents - CTSO Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTSO shares.
View CTSO analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12 month price targets for Cytosorbents' shares. Their CTSO share price forecasts range from $5.50 to $6.00. On average, they expect the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 89.8% from the stock's current price.
View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts.

Cytosorbents' stock was trading at $1.55 at the start of the year. Since then, CTSO shares have increased by 95.5% and is now trading at $3.03.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CTSO earnings forecast.

Cytosorbents Co. (NASDAQ:CTSO) posted its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical research company earned $9.76 million during the quarter, compared to analyst estimates of $9.96 million. Cytosorbents had a negative net margin of 114.61% and a negative trailing twelve-month return on equity of 80.80%. During the same period last year, the firm posted ($0.02) EPS.

Cytosorbents updated its fourth quarter 2022 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.40 million-$9.40 million, compared to the consensus revenue estimate of $8.90 million.

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Cytosorbents' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (2.26%), Eudaimonia Partners LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Al Kraus, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi.
View institutional ownership trends.

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTSO stock can currently be purchased for approximately $3.03.

Cytosorbents (NASDAQ:CTSO) has a market capitalization of $132.23 million and generates $43.17 million in revenue each year. The medical research company earns $-24,560,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

The company employs 221 workers across the globe.

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650.